FDA panel considers easing peptide restrictions

Key Points:

• The FDA advisory panel is holding a two-day meeting to evaluate seven experimental peptide therapies, including popular compounds like TB-500, BPC-157, and MOTs-C, which have not undergone large-scale safety and efficacy trials required for FDA approval.
• These peptides are widely promoted in the wellness community for benefits such as injury recovery, muscle growth, fat loss, skin health, and metabolism enhancement, despite limited human data and primarily preclinical animal studies.
• The meeting highlights a conflict between Health Secretary Robert F. Kennedy Jr.'s advocacy for lifting peptide restrictions and the FDA scientists' recommendation against allowing compounding pharmacies to produce these peptides due to safety concerns.
• The FDA committee, recently reshuffled with members linked to the peptide industry, will vote on four peptides on Thursday and three more on Friday, reviewing their potential use for conditions like migraines, ulcerative colitis, opioid withdrawal, and wound healing.
• While the panel's recommendations are influential, the FDA leadership retains final authority on whether these experimental peptides will be approved for broader clinical use.